Top in endocrinology: Inaccurate supplement labels; first fully implantable integrated CGM
Click Here to Manage Email Alerts
Findings from a case series study revealed that 83% of 30 dietary supplements that were marketed online for weight loss had inaccurate ingredient labels.
Additionally, some of the supplements contained substances listed on the U.S. Department of Defense’s prohibited dietary supplement ingredients list.
“No one should be put in harm’s way with predatory marketing of such supplements,” Patricia A. Deuster, PhD, MPH, FACSM, a professor in the department of military and emergency medicine at the Uniformed Services University of the Health Sciences in Bethesda, Maryland, told Healio. “Consumers should be confident that the products they might choose will not negatively impact their health, performance or readiness to serve.”
It was the top story in endocrinology last week.
Another top story was about the FDA’s recent authorization of the Eversense E3 continuous glucose monitoring (CGM) device (Senseonics Holdings and Ascensia Diabetes Care) for integration with insulin delivery systems. The device is the first fully implantable integrated CGM, according to the manufacturers.
Read these and more top stories in endocrinology below:
Most weight loss-promoting dietary supplements contain inaccurate ingredient labels
Dietary supplements marketed online to promote weight loss commonly have inaccurate labels and may include unsafe ingredients for the public to use, according to findings published in JAMA Network Open. Read more.
Fully implantable CGM receives FDA authorization for integration with insulin pumps
The FDA granted integrated continuous glucose monitoring designation to a fully implantable CGM, according to a press release. Read more.
FDA fast tracks PTH1 receptor agonist for treatment of hypoparathyroidism
The FDA granted fast track designation for an investigational parathyroid hormone 1 receptor agonist to treat hypoparathyroidism, according to an industry press release. Read more.
Missing insulin doses linked to lower time in range for adults with diabetes
Adults with diabetes who use a smart pen for both basal and bolus insulin delivery have a reduction in time in range with each injection they miss over a 14-day period, according to data published in Diabetes Care. Read more.
GLP-1 receptor agonist tied to similar thyroid cancer risk as DPP-IV, SGLT2 inhibitors
Adults who initiate a GLP-1 receptor agonist have a similar risk for developing thyroid cancer as those prescribed a DPP-IV inhibitor or an SGLT2 inhibitor, according to study findings published in The BMJ. Read more.